Answers are grounded in this paper and cite their sources.
Messenger RNA (mRNA) vaccines offer a flexible approach to colorectal cancer (CRC) immunotherapy, with applications ranging from postoperative residual disease to metastatic cancer. This narrative review examines antigen selection, RNA engineering, nanodelivery, and clinical development, drawing on literature available through 21 October 2026. Tumor-associated antigens, shared driver mutations, and personalized neoantigens offer different advantages in population coverage, specificity, and manufacturing. Their activity also depends on RNA chemistry and carrier design, including lipid composition, endosomal release, APC targeting, tissue distribution, stability, and repeated dosing. Early clinical studies have demonstrated antigen-specific T-cell responses in selected patients, while randomized melanoma data provide a benchmark for combining vaccination with checkpoint blockade. The termination of the CRC adjuvant autogene cevumeran monotherapy trial highlights the difficulty of translating immune priming into recurrence prevention. Antigen heterogeneity, impaired HLA presentation, stromal exclusion, and liver-associated immune suppression remain important barriers in CRC. Advances in neoantigen prediction, self-amplifying RNA, and mechanism-based combinations may improve vaccine design, but their clinical value will depend on disease-specific trials that account for manufacturing feasibility and established oncological endpoints. The available evidence remains heterogeneous, with small CRC cohorts and limited randomized outcomes; the non-systematic search also introduces potential selection bias.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: